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Abstract attributed to the high regularity of memories, PAs and
FPGAs, and the ease with which they can be tested and
reconfigured to avoid faulty elements. Digital microfluidics-
based biochips are also amenable to redundancy-based yield
enhancement. As in the case of memories, they contain 
regular arrays of small elements, and the elements are simple
and identical. Similar to FPGAs, reconfigurability is an
inherent property of these devices.
As microfluidics-based biochips become more complex,
manufacturing yield will have significant influence on
production volume and product cost. We propose an 
interstitial redundancy approach to enhance the yield of
biochips that are based on droplet-based microfluidics. In this
design method, spare cells are placed in the interstitial sites 
within the microfluidic array, and they replace neighboring
faulty cells via local reconfiguration. The proposed design
method is evaluated using a set of concurrent real-life
bioassays.
In this paper, we propose a scheme for incorporating
defect tolerance in the design of digital microfluidics-based
biochips. While spare rows/columns around a mesh-
connected array are often used in fault-tolerant processor
arrays and FPGAs [6], the property of “fluidic locality”
prevents the application of this simple redundancy technique
to microfluidic biochips. Due to the absence of programmable
interconnects such as switches between microfluidic cells, a
droplet is only able to move directly to the adjacent cells.
Thus, a faulty cell can only be replaced by its physically-
adjacent cells. Consequently, a complicated “shifted
replacement” process is required to utilize the spare cells
located in the boundary row/column; this results in an
unacceptable increase in the reconfiguration cost. 
1.    Introduction
Microfluidics-based biochips promise to revolutionize
clinical diagnostics, DNA sequencing, and other procedures
involving molecular biology [1]. In contrast to continuous-
flow microfluidic biochips consisting of permanently etched
micropumps, microvalves, and microchannels [1], droplet-
based microfluidic biochips relying on the manipulation of
individual droplets through electrowetting and referred to as 
“digital microfluidics” have been demonstrated [2]. Digital
microfluidics offer dynamic reconfigurability, whereby
groups of cells in a microfluidic array can be reconfigured to 
change their functionality during the concurrent execution of 
a set of bioassays. These features make digital microfluidics a 
promising platform for massively-parallel DNA analysis,
automated drug discovery, and real-time biomolecular
recognition.
We propose an interstitial redundancy approach to address
the above problem. In this approach, spare cells are placed in
the interstitial sites within the microfluidic array such that a 
spare cell can functionally replace any faulty cells that are
physically adjacent to it. This defect tolerance method owes
its effectiveness to the high utilization of local
reconfiguration. We apply this space redundancy technique to 
a new biochip design with hexagonal electrodes. Microfluidic
biochips with different levels of redundancy can be designed
to target given yield levels and manufacturing processes. We
introduce a metric called  “effective yield” to evaluate the
yield enhancement provided by these defect-tolerant designs.
A set of real-life bioassays, i.e., multiplexed in-vitro
diagnostics on human physiological fluids, is used to evaluate
the proposed method. Simulation results show that the yield
of a digital microfluidics-based biochip can be significantly
increased with the addition of interstitial redundancy and the
use of local reconfiguration.
Future advances in fabrication technology will allow
increased integration of microfluidic components in 
composite microsystems. The 2003 International Technology
Roadmap for Semiconductors (ITRS) anticipates that
microfluidic biochips will soon be integrated with electronic
components in system-on-chip (SOC) design [3]. It is
expected that several bioassays will then be concurrently
executed in a single microfluidic array [4]. However, as in the
case of integrated circuits, increase in density and area of 
microfluidics-based biochips will reduce yield, especially for 
new technology nodes. Low yield is a deterrent to large scale
and high-volume production, and it tends to increase
production cost. It will take time to ramp up yield learning
based on an understanding of defect types in such mixed-
technology SOCs. Therefore, defect-tolerant designs are 
especially important for the emerging marketplace.
_
The organization of the remainder of the paper is as
follows. In Section 2, we discuss related prior work. Section 3
presents an overview of digital microfluidics-based biochips.
It also introduces a new design based on hexagonal
electrodes. Section 4 discusses manufacturing defects and
briefly presents a unified test methodology. Reconfiguration
techniques for microfluidic biochips are also presented. In
Section 5, we introduce various defect-tolerant designs with
different levels of redundancy. The defect tolerance of these
designs is evaluated in Section 6. In Section 7, multiplexed in-
vitro diagnostics on human physiological fluids is used to
_______________________________
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Yield enhancement through space redundancy and 
reconfiguration has been successfully applied to memories,
processor arrays (PAs) and field-programmable gate arrays
(FPGAs)  [5, 6].   The success of  these  techniques  can  be
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evaluate the proposed yield improvement methodology.
Finally, conclusions are drawn in Section 8.
2.   Related Prior Work 
Defect tolerance techniques have been successfully used
for memory chips since the late 1970’s [5]. In contrast to 
memory arrays, few logic circuits have been designed with
built-in redundancy. The absence of regularity in these
circuits usually leads to high overhead. Regular circuits, such
as processor arrays and FPGAs require less redundancy; a 
number of defect tolerance techniques have been proposed to
enhance their yield [6, 7].
Figure 1: (a) Basic cell used in a digital microfluidics-based biochip; (b)
Digital microfluidics-based biochip with hexagonal electrodes.
droplets have been observed with velocities up to 20cm/s [12].
Furthermore, based on this principle, microdroplets can be
transported freely to any location on a two-dimensional array
without the need for pumps and valves. The configurations of 
the microfluidic array are programmed into a microcontroller
that controls the voltages of electrodes in the array.
Microelectromechanical systems (MEMS) is a relatively
young field compared to integrated circuits. It employs
micromachining techniques, such as surface micromachining
and bulk micromachining, in the fabrication process [8].
These processes are less mature than standard CMOS
manufacturing processes. As a result, the yield for MEMS
devices is often less than that for integrated circuits. Attempts
have been made in recent years to make MEMS defect-
tolerant. For example, design-for-manufacturing has been
incorporated in the design process for MEMS [9].
In the latest generation of microfluidic biochips,
hexagonal electrodes are being used to replace the
conventional square electrodes design; this close-packed
design is expected to increase the effectiveness of droplet
transportation in a 2-D array. The top view of a microfluidic
array with hexagonal electrodes is shown in Figure 1(b). A
droplet can be moved to an adjacent cell in six possible
directions. In this paper, we attempt to make this hexagonal
array defect-tolerant through space redundancy and local
reconfiguration.
Microfluidics differs from MEMS in the underlying
energy domains and in the working principles. Hence, defect
tolerance techniques for MEMS cannot be directly applied to
microfluidic biochips. Recent work has focused on a fault
classification and a unified test methodology for digital
microfluidics-based biochips [10, 11]. Faults are classified as
either manufacturing or operational, and techniques have been
developed to detect these faults by electrostatically controlling
and tracking the droplet motion. This cost-effective test 
methodology facilitates defect tolerance for digital
microfluidics-based biochips.
4. Manufacturing Defects and Reconfiguration
Techniques
Digital microfluidics-based biochips are fabricated using
standard microfabrication techniques, the details of which are
described in [13]. Microfluidic biochips exhibit behavior
resembling that of analog and mixed-signal devices.
Therefore, we can classify faults caused by the manufacturing
defects as being either catastrophic or parametric, along the
lines of fault classification for analog circuits [14]. 
Catastrophic (hard) faults lead to a complete malfunction of
the system, while parametric (soft) faults cause a deviation in 
system performance. A parametric fault is detectable only if 
this deviation exceeds the tolerance in system performance.
However, due to the underlying mixed technology and
multiple energy domains, microfluidic biochips exhibit failure
mechanisms and defects that are significantly different from
failure modes in integrated circuits.
3.   Digital Microfluidics-Based Biochips
Digital microfluidics-based biochips manipulate nanoliter-
volume droplets using electrowetting. The basic cell in a 
digital microfluidics-based biochip consists of two parallel
glass plates, shown in Figure 1(a). The bottom plate contains
a patterned array of individually controllable electrodes, and
the top plate contains a ground electrode. The droplets
containing biomedical samples are sandwiched between these
two plates, and surrounded by a filler medium such as silicone
oil. In addition, the droplets are insulated from the electrode
array by Parylene C (~800 nm), and a thin layer of
hydrophobic Teflon AF 1600 (~50 nm) is coated onto the top
and bottom plates to decrease the wettability of the surface. 
Catastrophic faults may be caused by the following
manufacturing defects:
 Dielectric breakdown: The breakdown of the dielectric at
high voltage levels creates a short between the droplet
and the electrode. When this happens, the droplet
undergoes electrolysis preventing further transportation.
Electrowetting is the basic principle of microdroplet
transportation wherein the interfacial tension of a droplet is 
modulated with an electric field. A control voltage is applied
to an electrode adjacent to the droplet and at the same time the
electrode just under the droplet is deactivated. Thus, an
accumulation of charge in the droplet/insulator interface over
the activated electrode results in a surface tension gradient,
which consequently causes the transportation of the droplet. 
By varying the electrical potential along a linear array of
electrodes, nanoliter-volume droplets can be transported along
this line of  electrodes. The  velocity of  the droplet  can  be
controlled by  adjusting the  control voltage (0 ~ 90 V),  and
 Short between adjacent electrodes: If a short occurs
between two adjacent electrodes, the two electrodes
shorted effectively form one longer electrode. When a
droplet resides on this electrode, it cannot overlap its 
adjacent electrodes. As a result, the actuation of the
droplet can no longer be achieved.
 Open in the metal connection between the electrode and 
the control source: This defect results in a failure in
activating the electrode for transport.
Manufacturing defects that cause parametric faults include
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geometrical parameter deviations. The deviation in insulator
thickness, electrode length and height between parallel plates
may exceed their tolerance value during fabrication.
Reconfiguration can be employed not only after the detection
of catastrophic faults, but also after the detection of 
parametric faults that cause significant performance
degradation
To test a biochip, stimuli droplets containing the normal
conducting fluid (e.g., KCL solution) from the droplet source
are transported through the array (traversing the cells) to
detect the faulty cells. Reconfiguration techniques can be used
to bypass faulty cells and increase yield. These
reconfiguration approaches can be divided into two categories.
The first category consists of techniques that do not add space
redundancy, i.e., spare cells, to the microfluidic array. Instead,
they attempt to tolerate the defect by using fault-free unused
cells. In order to achieve satisfactory yield using this method,
fault tolerance must be considered in the design procedure,
e.g., in the placement of microfluidic modules in the array.
Consequently, it leads to an increase in design complexity.
The second category of reconfiguration techniques is
application-independent because it incorporates physical
redundancy in the microfluidic array. Built-in spare cells can
be utilized to replace a defective cell. Since a faulty cell is 
replaced by a neighboring spare cell, these techniques are also
referred to as local reconfiguration.
Figure 2: Example of a microfluidic array with one single spare row.
though it is fault-free; see Figure 2(c). 
In order to address the problems resulting from
microfluidic locality, a new space redundancy approach,
termed interstitial redundancy [7], is proposed in this paper.
In this approach, spare cells are located in the interstitial sites
within the microfluidic array such that each spare cell is able
to functionally replace any one of the primary cells adjacent
to it. In contrast to redundancy based on boundary spare
rows/columns, interstitial redundancy offers a simple
reconfiguration scheme that effectively utilizes local
reconfiguration. We apply interstitial redundancy to a digital
microfluidics-based biochip with hexagonal electrodes. Such
defect-tolerant microfluidic arrays can incorporate different
levels of redundancy depending on the number and location
of spare cells. We next introduce some key definitions.
Definition 1: A defect-tolerant design for a digital
microfluidics-based biochip, denoted DTMB(s, p), has
interstitial spare cells such that each non-boundary primary
cell can be replaced by any one of s spare cells, and each
spare cell can be used to replace any one of p primary cells.
5. Defect-Tolerant Designs with Different
Redundancy Levels 
There are several ways to include spare cells in a defect-
tolerant microfluidic array. The first approach is to include
spare rows/columns around the microfluidic array. This is a 
common redundancy technique for PAs and FPGAs. However,
in contrast to these electronic arrays with well-defined roles of
logic blocks and interconnect, cells in a microfluidic array can
be used for storage, transport or other functional operations on
droplets. Due to the absence of separate interconnect entities,
droplets can only move to physically-adjacent cells. This
property is referred to as microfluidic locality. Consequently,
the functionality of a faulty cell can only be assumed by its
physically-neighboring cells in the array. Microfluidic locality
limits the reconfiguration capabilities of the spare
rows/columns if they are not adjacent to the faulty cell. In 
order to utilize the spare cell in the boundary rows/columns, a 
series of replacement, referred to as “shifted replacement” is
required. In shifted replacement, each faulty cell is replaced
by one of its fault-free adjacent cells, which is in turn replaced
by one of its adjacent cells, and so on, until a spare cell from
the boundary is incorporated in the reconfigured structure. In
many cases, this shifted replacement procedure will not only
involve the faulty module, but it will also require the
reconfiguration of fault-free modules. Therefore, it
significantly increases the complexity of the reconfiguration.
Figure 2 shows an example of a microfluidic array with a
single spare row. If one cell in Module 1 is faulty, Module 1 
can be only relocated to bypass the faulty cell, while other
modules remain unchanged; see  Figure 2(b). However,  if
there is one faulty cell in Module 3,  the shifted replacement
of Module 3  causes  the  reconfiguration of  Module  2  even
Definition 2: The redundancy ratio (RR) for a defect-tolerant
microfluidic array with interstitial redundancy is the ratio of
the number of spare cells in the array to the number of
primary cells. Clearly, for a DTMB(s, p) array of large size,
RR ≈ s/p.
(a) (b)
Spare cell
Primary cell
Node representing spare cell
Node representing primary cell
... ...... ...
... ...
... ... ... ... ... ...
... ... ... ...
Figure 3: Top view and graph model of DTMB(1, 6).
A DTMB(1, 6) design is shown in Figure 3(a). A
corresponding graph model, derived from the array, is shown
in Figure 3(b). Black nodes in the graph represent the primary
cells in the microfluidic biochip, while white nodes denote
spare cells. An edge between two nodes indicates that the two
cells represented by these nodes are physically adjacent in the
array. Each primary cell is adjacent to only one spare cell, and
every spare cell is adjacent to six primary cells. Therefore, the 
redundancy ratio for this array approaches 0.1667 as the array
size increases.
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Other defect-tolerant array designs, e.g., DTMB(2, 6),
DTMB(3, 6) and DTMB(4, 4), are shown in Figures 4 + 6. The
redundancy ratios of the different designs are listed in Table 1. 
(a) A DTMB(2, 6) design.
(b) An alternative DTMB(2, 6) design.
... ...
... ... ... ...
... ...
... ...
... ...
... ...
... ...
... ...
... ...
... ...
... ... ... ...
... ...
... ...
Figure 7: Yield for DTMB(1,6).
Since each primary cell is physically adjacent to only one
spare cell in DTMB(1, 6),  the  spare  assignment to  a  faulty 
cell is straightforward. Thus, its yield can be easily obtained
analytically. We can view DTMB(1, 6) as a composition of
identical clusters that consist of one spare cell and six primary
cells surrounding the spare cell . The yield Yc of any cluster in
DTMB(1, 6) is determined by the likelihood of having at most
one failed cell among these seven cells, i.e., 
A biochip with n primary cells can be
approximately divided into n/6 clusters. Since the cluster
failures are independent, the yield Y for this design is given
by
).1(7 67 pppY
C
−+=
( ) .)1( 66 np−776/n
C
ppY +==Y Figure 7 shows the yield 
for DTMB(1, 6)  for different values of p and n, and compares
it to the yield for a biochip without redundancy. Clearly, 
interstitial redundancy improves the yield of the microfluidic
biochip.
Figure 4: DTMB(2, 6) designs.
... ... ... ...
... ... ... ...
... ...
... ...
... ...... ...
Figure 5: An DTMB(3, 6) design.
For the defect-tolerant design with a higher level of
redundancy such as DTMB(2, 6), DTMB(3, 6) and DTMB(4,
4), it is hard to develop an analytical model to determine the
yield because their spare assignments are not straightforward.
We therefore address this problem using Monte-Carlo
simulation. During each run of the simulation, the cells in the
microfluidic array, including both primary and spare cells, are
randomly chosen to fail with probability p. We then check if 
these defects can be tolerated via local reconfiguration based
on the interstitial spare cells. This checking procedure is 
based on a graph matching approach as described below.
... ...
... ... ... ...
... ...
... ...... ...
... ...
... ...
Figure 6: An FTMB(4, 4) design.
Table 1: Redundancy ratios for the different defect-tolerant architecture.
Design DTMB(1, 6) DTMB(2, 6) DTMB(3, 6) DTMB(4, 4)
RR 0.1667 0.3333 0.5000 1.0000 We develop a bipartite graph model to represent the
relationship between faulty and spare cells in the microfluidic
array. A bipartite graph BG(A, B, E) is a graph whose nodes
can be partitioned into two sets, A  and B, and each edge in
6.    Estimation of Yield Enhancement
The effectiveness of various defect-tolerant designs can be
determined by estimating their enhanced yields.  The yield
analysis in this paper is based on the following assumption.
Assumption: Each single cell in the microfluidic array
including each primary and spare cell, has the same defect 
probability q. Moreover, the failures of the cells are
independent. Let p = 1− q denote the survival probability.
Note that the assumption of equal survival probabilities is
reasonable since each cell in the microfluidic array has the
same structure. In addition, the assumption of independent
failures is valid for random and small spot defects, which
result from imperfect materials and from undesirable chemical
and airborne particles.
Based on these assumptions, the yield for a defect-tolerant
design can be obtained in terms of p. We use both analytical
modeling and Monte-Carlo simulation.
Figure 8: Example of maximal bipartite matching model.
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levels is shown in Figure 10.  The number of primary cells is 
set to 100. As expected, the results show that a microfluidic
structure with   the higher  level  of  redundancy, such  as
DTMB(4, 4), is suitable for small values of p. On the other
hand, a lower level of redundancy, such as DTMB(1, 6) or
DTMB(2, 6), should be used when p is relatively high.
Figure 9: Yield estimation for DTMB(2,6), DTMB(3,6) and DTMB(4,4).
7.    Example: Multiplexed in-vitro Diagnostics
In this section, we evaluate the proposed defect-tolerant
design by applying it to a digital microfluidics-based biochip
used for multiplexed biomedical assays. The in-vitro
measurement of glucose and other metabolites, such as lactate, 
glutamate and pyruvate, in human physiological fluids plays a 
critical role in clinical diagnosis of metabolic disorders. For
example, the change of regular metabolic parameters in the
patient’s blood can signal organ damage or dysfunction prior
to observable microscopic cellular damages or other
symptoms. Recently, the feasibility of performing a
colorimetric enzyme-kinetic glucose assay on a digital
microfluidic biochip has been successfully demonstrated in
experiments [17].
E has one node in A and one node in B [15]. In our model,
nodes  in A represent  the  faulty  primary  cells  in  the
microfluidic array while nodes in B denote the fault-free spare
cells. An edge exists from a node a in A to a node b in B if 
and only if the faulty primary cell represented by a is
physically adjacent to the spare cell represented by b. An 
example is shown in Figure 8. A maximal matching for this
bipartite graph can be obtained using well-known techniques
[16]. If this maximal matching covers all nodes in A, it 
implies that all faulty cells can be replaced by their adjacent
fault-free spare cells through local reconfiguration. Otherwise,
this microfluidic biochip cannot be reconfigured. After 10000
simulation runs, the yield of this microfluidic array is
determined from the proportion of successful reconfigurations.
The simulation results for DTMB(2, 6), DTMB(3, 6) and
DTMB(4, 4) are shown in Figure 9, where n is the number of 
primary cells. 
The glucose assay performed on the biochip is based on
Trinder’s reaction, a colorimetric enzyme-based method [18].
The enzymatic reactions involved in the assay are:
O4HneQuinoneimiTOPSAAP-4O2H
OHAcidGluconicOOHGlucose
2
Peroxidase
22
22
OxidaseGlucose
22
+ →++
+ →++
In the presence of Glucose oxidase, glucose can be
enzymatically oxidized to gluconic acid and hydrogen
peroxide. Then, in the presence of peroxidase, the hydrogen
peroxide reacts with 4-amino antipyrine (4-AAP) and N-
ethyl-N-sulfopropyl-m-toluidine (TOPS) to form violet-
colored quinoneimine, which has an absorbance peak at 
545nm. Based on Trinder’s reaction, a complete glucose assay
can be performed following three steps, namely,
transportation, mixing and optical detection. A sample
droplet containing glucose and a reagent droplet containing
glucose oxidase, peroxidase, 4-AAP and TOPS, are dispensed
into the microfluidic array from their respective droplet
sources. They are then transported towards a mixer where the
sample and the reagent droplets are mixed. The mixed droplet
is transported onto a transparent electrode to enable
observation of the absorbance of the products of the
enzymatic reaction. Absorbance measurements are performed
with a green LED and a photodiode. The glucose
concentration can be measured from the absorbance, which is
related to the concentration of colored quinoneimine in the
droplet. Besides glucose assays, other metabolites such as 
lactate, glutamate, and pyruvate have been detected in a
digital microfluidic biochip recently. In addition to current
metabolites, a number of reagents can be added onto a chip to 
enable a multiplexed in-vitro diagnostics platform on different
human physiological fluids. Figure 11 shows a recently
fabricated microfluidic biochip used for multiplexed
biomedical assays [17]. In this biochip with square electrodes,
SAMPLE1 and SAMPLE2 contain glucose and REAGENT1
and REAGENT2 contain the reagents.
From Figure 9, it is clear that a higher level of redundancy
leads to a higher yield. However, adding more redundant cells
increases the array area and thereby manufacturing cost. To
measure yield enhancement relative to the increased array size,
we define the effective yield EY
as:  where n is the number of
primary cells, and N is the total number of cells in the
microfluidic array. The parameter EY represents the tradeoff 
between yield enhancement and increase in manufacturing
cost. The variation of EY with p for different redundancy
),1/()/( RRYNnYEY +=×=
In this first design and demonstration, only cells used for
the bioassays were fabricated; no spare cells were included in
Figure 10: Effective yield for different levels of redundancy.
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Figure 11: Fabricated biochip used for multiplexed bioassays.
Primary cell used in biomedical assays
Unused Primary cellSpare cell Faulty cell
Spare cell used in reconfiguration
(a) (b)
Figure 13: Yield estimation for the DTMB(2,6)-based design in the 
presence of multiple defects.
be a deterrent to high-volume production and  it  will  increase
production cost. The proposed defect-tolerant design approach
will therefore be especially useful for the emerging
marketplace.
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